RE: Results - not quite as *MEH* as they look...7 Mar 2024 12:28
/continued from my last post...
For me, the bottom line is that much of the operating profit flatness is driven by the accounting of £0.5bn of exceptional items (longevity, etc) that (hopefully!) won't be there next year.
The underlying growth in the business is good. The weakest areas of the business appear to be:
- LGIM
- Aviva seems to be taking market share of workplace pensions (new savings down 14% YoY)
- US PRT business is disappointingly down 18%
Whilst many are disappointed at the lack of an announcement of a buyback, I find the following more interesting than it looks:
"The Board believes it has considerable opportunities available to deliver attractive returns to shareholders by retaining and investing capital within the Group.
The Board will at the same time continually assess these investment opportunities against the relative attractiveness of returning capital to shareholders either through a buyback or a programme of buybacks.
If, at any point, the Board believes that capital would be best deployed in this way, or if the Board believed it had surplus capital, it would not hesitate to return capital to shareholders."
This is new language. It wasn't in last year's document.
To me, it says "We hear you on buybacks. We think money is better invested in the business for the moment, but we're not ruling out a buyback. Wait to listen to our plans."
Overall, not as *MEH* as it looks.
It's easy to try to compare LGEN, AV. and PHNX (and MNG, JUST, etc...). But important to remember that they have significant differences in the shape of their businesses. If you'll excuse the overly simplistic analogies:
- Aviva has a huge general insurance business that flatters performance when you premiums rise. It's much more of a gin business - you make it; sell it and take profit more or less immediately.
- LGEN is much more a whisky distillery - you make (actually sell) stuff that needs to mature (in the CSM+RA pot) and you realise profit later
- PHNX is more like a whisky dealer that's bought up lots of stocks that are slowly maturing can be incrementally sold over time.
I suspect that JATW is correct that Simoes is likely to trade sale the housing business. It makes more sense (to me) to have a strategic partnership with someone like Vistry for the affordable / social rent homes and someone like Barratt for the homes for sale.
I am a long term holder here and used to work in a senior role in the business - so I hopefully have a better understanding than most. But it's a complex business.
I can see arguments for selling and arguments for holding - so not a recommendation either way and please DYOR.